Chonluten

Chonluten is a synthetic tripeptide composed of the amino acid sequence Glutamic acid–Aspartic acid–Glycine (Glu-Asp-Gly / EDG). It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson bioregulator peptide program. Its naturally derived counterpart, Bronchogen, was originally isolated from bronchial tissue; Chonluten is the synthesized equivalent, produced from constituent amino acids to reproduce the active signaling sequence in a precisely defined molecular structure.

Chonluten belongs to the class of short regulatory peptides known as cytogens or bioregulators — low-molecular-weight compounds (typically 2–4 residues) proposed to exhibit tissue-specific modulation of gene expression. Unlike conventional compounds that act through receptor agonism or enzyme inhibition, Khavinson bioregulators are hypothesized to interact directly with specific complementary DNA sequences in the promoter regions of target genes, influencing transcription rather than initiating a downstream surface-receptor cascade.

Chonluten's documented target tissue is the bronchopulmonary system, where it has been examined in models of respiratory epithelial cell biology, bronchial gene expression, and age-associated changes in pulmonary tissue. In the literature it is associated with modulation of stress-response genes (c-Fos, HSP70), antioxidant enzymes (SOD), inflammatory mediators (COX-2, TNF-α), and epithelial barrier maintenance. It is frequently paired conceptually with Bronchogen (AEDL), which targets overlapping but complementary pathways in bronchial tissue.

Disclaimer: This product is intended strictly for laboratory and in vitro applications only. It is NOT for human consumption, ingestion, injection, or any in vivo use, and is not approved for diagnostic, therapeutic, cosmetic, or veterinary applications. Handle using appropriate laboratory safety procedures and personal protective equipment.